Paul J Hesketh
Overview
Explore the profile of Paul J Hesketh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
3541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jordan K, Chan A, Gralla R, Jahn F, Rapoport B, Ruhlmann C, et al.
Support Care Cancer
. 2023 Dec;
32(1):53.
PMID: 38129530
Purpose: Our goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) since the 2016 MASCC/ESMO antiemetic update...
2.
Scotte F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh P, et al.
Support Care Cancer
. 2023 Dec;
32(1):45.
PMID: 38114821
Purpose: Review the literature to update the MASCC guidelines from 2015 for controlling nausea and vomiting with systemic cancer treatment of moderate emetic potential. Methods: A systematic literature review was...
3.
Iyengar P, All S, Berry M, Boike T, Bradfield L, Dingemans A, et al.
Pract Radiat Oncol
. 2023 Jun;
13(5):393-412.
PMID: 37294262
Purpose: This joint guideline by American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) was initiated to review evidence and provide recommendations regarding the...
4.
Singh N, Temin S, Baker Jr S, Blanchard E, Brahmer J, Celano P, et al.
J Clin Oncol
. 2022 Jul;
40(28):3323-3343.
PMID: 35816668
Purpose: To provide evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer without driver alterations....
5.
Singh N, Temin S, Baker Jr S, Blanchard E, Brahmer J, Celano P, et al.
J Clin Oncol
. 2022 Jul;
40(28):3310-3322.
PMID: 35816666
Purpose: To provide evidence-based recommendations updating the 2021 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) with driver...
6.
Hanna N, Robinson A, Temin S, Baker Jr S, Brahmer J, Ellis P, et al.
J Clin Oncol
. 2021 Feb;
39(9):1040-1091.
PMID: 33591844
Purpose: To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic...
7.
Development of a Novel Communication Liaison Program to Support COVID-19 Patients and Their Families
Lipworth A, Collins E, Keitz S, Hesketh P, Resnic F, Wozniak J, et al.
J Pain Symptom Manage
. 2020 Nov;
61(1):e1-e10.
PMID: 33246074
In the spring of 2020, our hospital faced a surge of critically ill coronavirus disease 2019 patients, with intensive care unit (ICU) occupancy peaking at 204% of the baseline maximum...
8.
Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R, et al.
J Clin Oncol
. 2020 Jul;
38(24):2782-2797.
PMID: 32658626
Purpose: To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens and to provide recommendations on the use of dexamethasone as a prophylactic antiemetic in patients receiving...
9.
Hanna N, Schneider B, Temin S, Baker Jr S, Brahmer J, Ellis P, et al.
J Clin Oncol
. 2020 Jan;
38(14):1608-1632.
PMID: 31990617
Purpose: The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) without driver...
10.
Goldberg M, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, et al.
PLoS One
. 2018 Nov;
13(11):e0208097.
PMID: 30481207
After sequential treatment with first- and third-generation EGFR tyrosine kinase inhibitors (TKIs), EGFR-mutant non-small cell lung cancers frequently harbor multiple resistance mutations in exon 20 of EGFR including T790M, mediating...